Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Fujifilm Diosynth Biotechnologies UK Limited has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This filing is situated within 1 distinct art unit, reflecting a specific technical classification for the company's current application. The focus within a single art unit suggests a highly specialized technical disclosure that aligns with the expertise of that particular examination group. For the company, this concentration allows for a deep understanding of the specific requirements and precedents of the assigned unit.
The portfolio involves a distinct examiner. STEADMAN, DAVID J is the busiest examiner for the company, currently managing the pending office action. This individual is responsible for the entirety of the company's active prosecution activity. For the company, this means that all current feedback from the patent office in the Biotechnology & Pharmaceuticals area comes from a single person. This one-on-one interaction can lead to a more focused dialogue between the applicant and the examiner, potentially streamlining the path toward a final resolution on the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEADMAN, DAVID J | 1 | 57.7% | +29.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18719423 | SEQUENCES AND METHODS FOR PRODUCTION OF RECOMBINANT BIOLOGICAL MOLECULES IN VESICLES | STEADMAN, DAVID J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18719423 | SEQUENCES AND METHODS FOR PRODUCTION OF RECOMBINANT BIOLOGICAL MOLECULES IN VESICLES | STEADMAN, DAVID J | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18719423 | SEQUENCES AND METHODS FOR PRODUCTION OF RECOMBINANT BIOLOGICAL MOLECULES IN VESICLES | STEADMAN, DAVID J | 1656 | §101§102§112 | Final Rejection | — | Pending | Jun 13, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFujifilm Diosynth Biotechnologies UK Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
David J Steadman has the most, with 1 of Fujifilm Diosynth Biotechnologies UK Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.